CRISPR-Cas9-mediated gene therapy in lung cancer
Abstract As the largest cause of cancer-related deaths worldwide, pulmonary cancer is the most common form of the disease. Several genetic, epigenetic, and environmental factors come into play during the multi-step mechanism of tumorigenesis. The heterogeneity that makes discovering successful therapeutics for pulmonary cancer problematic is significantly influenced by the epigenetic landscape, including DNA methylation, chromatin architecture, histone modifications, and noncoding RNA control. Clinical activity of epigenetic-targeted medicines has been reported in hematological tumors, and these compounds may also have therapeutic effects in solid tumors. Over the course of the past few years, some researchers have successfully modified the expression of genes in cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) technique. The utilization of this technology allows for the induction of site-specific mutagenesis, epigenetic alterations, and the regulation of gene expression. This study will present an overview of the primary epigenetic alterations seen in pulmonary cancer, as well as a summary of therapeutic implications for targeting epigenetics in the management of pulmonary cancer, with a particular emphasis on the technique known as CRISPR/Cas9..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Revista de oncología - 25(2022), 5 vom: 10. Dez., Seite 1156-1166 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kazemizadeh, Hossein [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s12094-022-03039-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR050125451 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR050125451 | ||
| 003 | DE-627 | ||
| 005 | 20230421064743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230421s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12094-022-03039-8 |2 doi | |
| 035 | |a (DE-627)SPR050125451 | ||
| 035 | |a (SPR)s12094-022-03039-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kazemizadeh, Hossein |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CRISPR-Cas9-mediated gene therapy in lung cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO) 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract As the largest cause of cancer-related deaths worldwide, pulmonary cancer is the most common form of the disease. Several genetic, epigenetic, and environmental factors come into play during the multi-step mechanism of tumorigenesis. The heterogeneity that makes discovering successful therapeutics for pulmonary cancer problematic is significantly influenced by the epigenetic landscape, including DNA methylation, chromatin architecture, histone modifications, and noncoding RNA control. Clinical activity of epigenetic-targeted medicines has been reported in hematological tumors, and these compounds may also have therapeutic effects in solid tumors. Over the course of the past few years, some researchers have successfully modified the expression of genes in cells using the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas (CRISPR-associated proteins) technique. The utilization of this technology allows for the induction of site-specific mutagenesis, epigenetic alterations, and the regulation of gene expression. This study will present an overview of the primary epigenetic alterations seen in pulmonary cancer, as well as a summary of therapeutic implications for targeting epigenetics in the management of pulmonary cancer, with a particular emphasis on the technique known as CRISPR/Cas9. | ||
| 650 | 4 | |a CRISPR |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NSCLC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SCLC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Epigenetic |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Cancer therapy |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Kashefizadeh, Alireza |0 (orcid)0000-0001-7997-0365 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revista de oncología |d Barcelona : Doyma, 2000 |g 25(2022), 5 vom: 10. Dez., Seite 1156-1166 |w (DE-627)SPR024246131 |w (DE-600)2143451-7 |x 1578-195X |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2022 |g number:5 |g day:10 |g month:12 |g pages:1156-1166 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12094-022-03039-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2022 |e 5 |b 10 |c 12 |h 1156-1166 | ||